All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F23%3A10467841" target="_blank" >RIV/00216208:11140/23:10467841 - isvavai.cz</a>

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=a0SbQ8tT9Q" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=a0SbQ8tT9Q</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3390/cancers15102782" target="_blank" >10.3390/cancers15102782</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

  • Original language description

    Simple Summary: Cancers in the urinary bladder and kidney are common in men and rarer in women. Cigarette smoking is a shared risk factor for both of these cancers. Some 50 years ago, survival in these cancers was low, and it was worse for kidney than bladder cancer. In the present study, we could show improvement in survival for these cancers in the Nordic countries, and similar improvements have also been observed in other countries. Kidney cancer survival improved remarkably well, as 50 years ago, only 20-30% of the patients survived 5 years, but currently, some 75% survive 5 years. In male bladder cancer, 5-year survival is still somewhat better than survival in kidney cancer, but female kidney cancer survival has caught up with that of bladder cancer. The reasons for this positive development for both of these cancers is earlier diagnosis as patients with blood in urine are readily taken for examinations. Additionally, treatment has become more efficient, and continuously new medications are being introduced. Kidney and bladder cancers share etiology and relatively good recent survival, but long-term studies are rare. We analyzed survival for these cancers in Denmark, Finland, Norway (NO), and Sweden (SE) over a 50-year period (1971-2020). Relative 1- and 5-year survival data were obtained from the NORDCAN database, and we additionally calculated conditional 5/1-year survival. In 2016-2020, 5-year survivals for male kidney (79.0%) and bladder (81.6%) cancers were best in SE. For female kidney cancer, NO survival reached 80.0%, and for bladder cancer, SE survival reached 76.1%. The magnitude of 5-year survival improvements during the 50-year period in kidney cancer was over 40% units; for bladder cancer, the improvement was over 20% units. Survival in bladder cancer was worse for women than for men, particularly in year 1. In both cancers, deaths in the first year were approximately as many as in the subsequent 4 years. We could document an impressive development for kidney cancer with tripled male and doubled female 5-year survival in 50 years. Additionally, for bladder cancer, a steady improvement was recorded. The current challenges are to curb early mortality and target treatment to reduce long-term mortality.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    <a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancers

  • ISSN

    2072-6694

  • e-ISSN

    2072-6694

  • Volume of the periodical

    15

  • Issue of the periodical within the volume

    10

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    12

  • Pages from-to

    2782

  • UT code for WoS article

    000997031900001

  • EID of the result in the Scopus database

    2-s2.0-85160846611